글로벌 Rho 키나제(ROCKs) 억제제 시장 – 2030년까지의 산업 동향 및 예측

Rho Kinases (ROCKs) 억제제 시장 분석 및 규모

증가하는 암 인구와 새로운 치료법을 찾는 비율의 증가는 Rho Kinases(ROCKs) 억제제 시장 성장에 긍정적인 지표로 작용할 수 있습니다. 이에 더하여 강력한 연구 개발 활동도 시장 지위를 높일 수 있습니다. 현재 수많은 회사가 이 분야에서 일하고 있으며, 12개 이상의 활성 제품으로 구성된 강력한 파이프라인을 만들고 있습니다.  

 Data Bridge Market Research는 2023-2030년 예측 기간 동안 Rho Kinases(ROCKs) 억제제 시장의 성장률을 분석합니다. Rho Kinases(ROCKs) 억제제 시장의 예상 CAGR은 언급된 예측 기간 동안 약 6.60%인 경향이 있습니다. 시장은 2022년에 614억 달러로 평가되었으며 2030년까지 1,023억 8,000만 달러까지 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

Rho 키나제(ROCK) 억제제 시장 범위 및 세분화

시장 정의

Rho kinases (ROCKs) inhibitor is a type of rho-associated protein kinase inhibitor a therapeutics belonging to the serine-threonine family. Their function is to target the small GTP-binding protein Rho network that plays an essential role in regulating cell cycle control. ROCK is recommended to be a therapeutic target in several diseases such as ophthalmic diseases, cardiovascular diseases, neurological disorders, autoimmune diseases, and cancer.

Rho Kinases (ROCKs) Inhibitors Market Dynamics

Drivers

• Growing Prevalence of Cancer

Cancer is one of the leading cause of death worldwide, accounting for around 10 million deaths in 2020. The most common in 2020 was breast cancer, about 2.26 million cases. Breast cancer is the most common type, with 290,560 new cases anticipated in the U.S. in 2022. The next most incident cancers are prostate cancer and lung cancer. There was an expected 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020 worldwide. Thus, this factor increases the demand of Rho Kinases (ROCKs), further boosting the market growth.

Opportunities

• Increasing Cases of Glaucoma

Glaucoma is a top cause of irreversible blindness in the U.S. and the world. More than three million Americans are surviving with glaucoma, and 2.7 million people aged 40 years and older are affected by its most common form, open-angle glaucoma. Blindness or low vision affects around 3.3 million Americans age 40 years and above. More than 11 million individuals are expected to be bilaterally blind because of glaucoma in 2020. In the majority of the cases, blindness can be prevented with proper control and treatment. In the U.S., blindness is the third most feared health problem, after cancer and cardiac attacks. In this regard, ROCK inhibitors are used to decrease intraocular pressure, which is found to be beneficial for glaucoma, by smoothening the trabecular meshwork cells of the eye which is critical for the drainage of ocular fluid. Thus, this factor helps in increasing the market growth.

• Growing Healthcare Expenditure And Government Support

The rising incidence of cancer, the growing awareness for the disease and the associated treatment is also enhancing. Numerous government initiatives tend to provide better and more convenient treatments and favourable reimbursement policies that are anticipated to increase the industry growth. Additionally, growing acceptance of advanced therapies is projected to drive the market.

Restraints/Challenges

• High Cost of Treatment

The increasing expenditure related with the medications hinder the market growth. Numerous genetic drugs cost high and people in developing and underdeveloped countries, causing the under treatment of several patients. This impedes the market growth.

This Rho Kinases (ROCKs) inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Rho Kinases (ROCKs) inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Rho Kinases (ROCKs) Inhibitors Market Scope

The Rho Kinases (ROCKs) inhibitors market is segmented on the basis of drugs, indication, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Netarsudil
• Ripasudil Hydrochloride Hydrate
• Fasudil
• Others

Indication

• Cerebral Vasospasm
• Glaucoma
• Others

Route of Administration

• Oral
• Topical
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Rho Kinases (ROCKs) Inhibitors Market Regional Analysis/Insights

The Rho Kinases (ROCKs) inhibitors market is analyzed and market size insights and trends are provided by drugs, indication, route of administration, end-users and distribution channel as referenced above.

The major countries covered in the Rho Kinases (ROCKs) inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for Rho Kinases (ROCKs) inhibitors market throughout the forecasted period because of the high incidence rate of glaucoma, increasing awareness and development activities for Rho kinases (ROCKs) inhibitor-based therapeutics. Furthermore, the increasing presence of refined clinical facilities and surge in better treatment seeking rates of patients suffering from the eye disorders is boosting the growth of the market.

아시아 태평양 지역은 의료 인프라의 건전한 개선과 엄청난 경제 발전으로 시장을 지배하고 있습니다. 또한, 의료 인프라의 건전한 개선은 시장 성장을 촉진합니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 또한 글로벌 브랜드의 존재와 가용성, 그리고 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.   

경쟁 환경 및 글로벌 Rho 키나제(ROCK) 억제제 시장 점유율 분석

Rho Kinases(ROCKs) 억제제 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 제공된 위의 데이터 포인트는 Rho Kinases(ROCKs) 억제제 시장과 관련된 회사의 초점에만 관련이 있습니다.

Rho Kinases(ROCKs) 억제제 시장에서 활동하는 주요 기업은 다음과 같습니다.

• Kowa Pharmaceuticals America, Inc. (미국)
• 센주제약 주식회사(일본)
• 노바티스 AG(스위스)
• AERIE PHARMACEUTICALS, INC. (미국)
• Redx Pharma Plc (영국)

SKU-52862